Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
OBJECTIVE: Aromatase inhibitors (AI) treatment leads to an increased risk of bone loss and fractures. In a group of women with early breast cancer (EBC) and baseline Vitamin D deficiency (<30 ng/ml) who are treated with AI, we aim to describe: serum levels of Vitamin D, bone mineral density...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1826300425065725952 |
|---|---|
| author | Nogues, X Servitja, S Peña, M Prieto-Alhambra, D Nadal, R Mellibovsky, L Albanell, J Diez-Perez, A Tusquets, I |
| author_facet | Nogues, X Servitja, S Peña, M Prieto-Alhambra, D Nadal, R Mellibovsky, L Albanell, J Diez-Perez, A Tusquets, I |
| author_sort | Nogues, X |
| collection | OXFORD |
| description | OBJECTIVE: Aromatase inhibitors (AI) treatment leads to an increased risk of bone loss and fractures. In a group of women with early breast cancer (EBC) and baseline Vitamin D deficiency (<30 ng/ml) who are treated with AI, we aim to describe: serum levels of Vitamin D, bone mineral density (BMD), calcium intake, and the increase of serum 25(OH)D accomplished in 3 months of treatment with Vitamin D supplements. STUDY DESIGN: Prospective, non-randomized clinical trial. METHODS: In 232 consecutively included women with EBC in treatment with AI, we assessed baseline calcium intake, serum levels of 25(OH)D, BMD and, spine X-ray. All received Calcium and Vitamin D supplements, and those with vitamin deficiency received 16,000 IU Vitamin D every 2 weeks. Serum levels of 25(OH)D were newly assessed after treatment. All the baseline evaluation was performed before starting AI treatment. RESULTS: Mean age at baseline (+/-SD) was 63.2+/-8.8 years. In 150 (64.9%) cases, the women had been treated previously with tamoxifen; 101 (43.7%) started exemestane, 119 (51.5%) letrozole, and 11 (4.8%) anastrozole. The AI were initiated within 6 weeks after surgery or after the last cycle of chemotherapy. At baseline, 88.1% had 25(OH)D levels <30 ng/ml, 21.2% had severe deficiency (<10 ng/ml), and 25% of the participants had osteoporosis. Mean daily calcium intake was low (841+/-338). We found a significant association between 25(OH)D levels and BMD at baseline, which remained significant in femoral neck BMD after multivariate adjustment. Plasma 25(OH)D levels improved significantly at 3 months follow-up in those treated with high dose Vitamin D supplements: mean increase 32.55 ng/ml (95%CI 28.06-37.03). CONCLUSIONS: Our study suggests a high prevalence of commonly unrecognized Vitamin D deficiency in women with EBC treated with AI, a known osteopenic agent. Our results support the need for a routine assessment of 25(OH)D levels and, when necessary, supplementation in these patients. |
| first_indexed | 2024-03-07T05:16:58Z |
| format | Journal article |
| id | oxford-uuid:dd8a1ae6-8221-49e7-9f10-445ab796bb2c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:16:58Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:dd8a1ae6-8221-49e7-9f10-445ab796bb2c2022-03-27T09:25:48ZVitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:dd8a1ae6-8221-49e7-9f10-445ab796bb2cEnglishSymplectic Elements at Oxford2010Nogues, XServitja, SPeña, MPrieto-Alhambra, DNadal, RMellibovsky, LAlbanell, JDiez-Perez, ATusquets, I OBJECTIVE: Aromatase inhibitors (AI) treatment leads to an increased risk of bone loss and fractures. In a group of women with early breast cancer (EBC) and baseline Vitamin D deficiency (<30 ng/ml) who are treated with AI, we aim to describe: serum levels of Vitamin D, bone mineral density (BMD), calcium intake, and the increase of serum 25(OH)D accomplished in 3 months of treatment with Vitamin D supplements. STUDY DESIGN: Prospective, non-randomized clinical trial. METHODS: In 232 consecutively included women with EBC in treatment with AI, we assessed baseline calcium intake, serum levels of 25(OH)D, BMD and, spine X-ray. All received Calcium and Vitamin D supplements, and those with vitamin deficiency received 16,000 IU Vitamin D every 2 weeks. Serum levels of 25(OH)D were newly assessed after treatment. All the baseline evaluation was performed before starting AI treatment. RESULTS: Mean age at baseline (+/-SD) was 63.2+/-8.8 years. In 150 (64.9%) cases, the women had been treated previously with tamoxifen; 101 (43.7%) started exemestane, 119 (51.5%) letrozole, and 11 (4.8%) anastrozole. The AI were initiated within 6 weeks after surgery or after the last cycle of chemotherapy. At baseline, 88.1% had 25(OH)D levels <30 ng/ml, 21.2% had severe deficiency (<10 ng/ml), and 25% of the participants had osteoporosis. Mean daily calcium intake was low (841+/-338). We found a significant association between 25(OH)D levels and BMD at baseline, which remained significant in femoral neck BMD after multivariate adjustment. Plasma 25(OH)D levels improved significantly at 3 months follow-up in those treated with high dose Vitamin D supplements: mean increase 32.55 ng/ml (95%CI 28.06-37.03). CONCLUSIONS: Our study suggests a high prevalence of commonly unrecognized Vitamin D deficiency in women with EBC treated with AI, a known osteopenic agent. Our results support the need for a routine assessment of 25(OH)D levels and, when necessary, supplementation in these patients. |
| spellingShingle | Nogues, X Servitja, S Peña, M Prieto-Alhambra, D Nadal, R Mellibovsky, L Albanell, J Diez-Perez, A Tusquets, I Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. |
| title | Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. |
| title_full | Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. |
| title_fullStr | Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. |
| title_full_unstemmed | Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. |
| title_short | Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. |
| title_sort | vitamin d deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer |
| work_keys_str_mv | AT noguesx vitaminddeficiencyandbonemineraldensityinpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT servitjas vitaminddeficiencyandbonemineraldensityinpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT penam vitaminddeficiencyandbonemineraldensityinpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT prietoalhambrad vitaminddeficiencyandbonemineraldensityinpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT nadalr vitaminddeficiencyandbonemineraldensityinpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT mellibovskyl vitaminddeficiencyandbonemineraldensityinpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT albanellj vitaminddeficiencyandbonemineraldensityinpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT diezpereza vitaminddeficiencyandbonemineraldensityinpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT tusquetsi vitaminddeficiencyandbonemineraldensityinpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer |